Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: Reproducibility and correlations of the 6-min walk test

Annals of the Rheumatic Diseases

Volumn 66, Issue 2, 2007, Pages 169-173

  Buch, M H ^b   Denton, C P ^c   Furst, D E ^d   Guillevin, L ^e   Rubin, L J ^f   Wells, A U ^g   Matucci Cerinic, M ^h   Riemekasten, G ⁱ   Emery, P ^j   Chadha Boreham, H ^k   Charef, P ^k   Roux, S ^k   Black, C M ^c   Seibold, J R ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Universite Rene Descartes ^*  (France)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k ACTELION PHARMACEUTICALS LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCREENING; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 33846892076     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.054866     Document Type: Article

References (27)

1. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcomes of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
2. Mukerjee D, St George D, Knight C, Denton CP, Davar J, Black CM, et al. Prevalence and outcome in systemic sclerosis associated pulmonary hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
3. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283- 9.
4. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-50.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. American Thoracic Society. Standardisation of spirometry, 1994 update. Am J Respir Crit Care Med 1994;152:1107-36.
7. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med 1995;152:2185-98.
8. American Thoracic Society. ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 2002;166:111-17.
9. Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnea during exercise. Clin Sci 1989;76:277-82.
10. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. OMERACT 6. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
11. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests. Reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:1150-7.
12. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin U, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
13. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
14. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
15. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001;119:256-70.
16. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919- 23.
17. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003;15:748-55.
18. Wells AU, Desai SR, Rubens MB, Goh NSL, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiological index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167:962-9.
19. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos P, Pantelidis P, et al. Histopatholocjic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6.
20. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, for the SLS Research Group, et al. The Scleroderma Lung Study: oral cyclophosphamide versus placebo for the treatment of scleroderma-related interstitial lung disease. N Engl J Med 2006;354:2655-66.
21. Hoyles RK, Ellis RW, Herrick AL, McHugh NJ, Foley NM, Pearson SB, et al. Fibrosing alveolitis in scleroderma trial (FAST) - a multicentre prospective randomized double-blind placebo-controlled trial [abstract]. Arthritis Rheum 2005;52:L29.
22. Kazzam E, Waldenstrom A, Landelius J, Hallgren R, Arvidsson A, Caidahl K. Non-invasive assessment of left ventricular diastolic function in patients with systemic sclerosis. J Intern Med 1990;228:183-92.
23. Kazzam E, Caidahl K, Hallgren R, Johansson C, Waldenstrom A. Mitral regurgitation and diastolic flow profile in systemic sclerosis. Int J Cardiol 1990;29:357-63.
24. Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F, et al. Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum 2005;34:721-7.
25. Lindqvist P, Caidahl K, Neuman-Andersen G, Ozolins C, Rantapaa-Dahlqvist S, Waldenstrom A, et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis. Chest 2005;128:755-63.
26. Dabaghi SF, Rokey R, Rivera JM, Saliba WI, Majid PA. Comparison of echocardiographic assessment of cardiac hemodynamics in the intensive care unit with right-sided cardiac catheterization. Am J Cardiol 1995;76:392-5.
27. Raghu G, Lasky JA, Costabel U, Brown KK, Cottin V, Thomeer M, et al. A randomized placebo controlled trial assessing the efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF). Chest 2005;128:496S.